Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Center for International Blood and Marrow Transplant Research
SWOG Cancer Research Network
National Institutes of Health Clinical Center (CC)
AvenCell Therapeutics, Inc.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Dana-Farber Cancer Institute
Allogene Therapeutics
Genmab
Allogene Therapeutics
Allogene Therapeutics
Ossium Health, Inc.
Lyell Immunopharma, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dartmouth-Hitchcock Medical Center
Essen Biotech
Celgene
Center for International Blood and Marrow Transplant Research
University of Wisconsin, Madison
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Celgene
Fate Therapeutics
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
St. Jude Children's Research Hospital
University of Ulm
University of Arizona
Case Comprehensive Cancer Center
Centre Antoine Lacassagne
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Universität des Saarlandes
University Hospital Southampton NHS Foundation Trust
European Organisation for Research and Treatment of Cancer - EORTC
Dana-Farber Cancer Institute
Takeda
University Health Network, Toronto
National Institutes of Health Clinical Center (CC)
Artiva Biotherapeutics, Inc.
City of Hope Medical Center
University of Chicago
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Janssen Research & Development, LLC
CARGO Therapeutics
Institute of Hematology & Blood Diseases Hospital, China
Thomas Jefferson University
City of Hope Medical Center
Miltenyi Biomedicine GmbH